2. Search Result
Search Result
Results for "

atopic

" in MedChemExpress (MCE) Product Catalog:

134

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

6

Biochemical Assay Reagents

3

Peptides

27

Inhibitory Antibodies

12

Natural
Products

5

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145551
    Atinvicitinib

    		Others Inflammation/Immunology
    Atinvicitinib is a kind of pyrazole compound. Atinvicitinib has the potential for the research of atopic dermatitis (extracted from patent WO2021123094A1) .
    Atinvicitinib
  • HY-P99301
    Lokivetmab

    Anti-Canine IL31 Recombinant Antibody; CAN34D3-65; PF-06443537

    		 Interleukin Related Inflammation/Immunology
    Lokivetmab (Anti-Canine IL31 Recombinant Antibody) is an anti-canine IL-31 monoclonal antibody. Lokivetmab inhibits IL-31-mediated activation of pruritogenic signals in peripheral sensory neurons and reduces TH2-weighted inflammation. Lokivetmab demonstrates long-term efficacy in controlling pruritus and improving skin lesions in dogs with canine atopic dermatitis (CAD). Lokivetmab can be used for the research of atopic dermatitis (AD) in dogs .
    Lokivetmab
  • HY-B1365
    Prednicarbate

    		Glucocorticoid Receptor Inflammation/Immunology
    Prednicarbate is a topical corticosteroid agent. Prednicarbate can be used for the research of inflammatory skin diseases, such as atopic dermatitis .
    Prednicarbate
  • HY-P991280
    BMS-981164

    		Interleukin Related Inflammation/Immunology
    BMS-981164 is a human IgG1-kappa anti-IL31 monoclonal antibody. The isotype control of BMS-981164 can be referenced to Human IgG1 kappa, Isotype Control (HY-P99001). BMS-981164 can be used in research related to atopic dermatitis .
    BMS-981164
  • HY-131707
    LEO 39652

    		Phosphodiesterase (PDE) Inflammation/Immunology
    LEO 39652 is a dual-soft PDE4 inhibitor with IC50s of 1.2 nM, 1.2 nM, 3.0 nM and 3.8 nM for PDE4A, PDE4B, PDE4C and PDE4D, respectively. LEO 39652 also inhibits TNF-α with an IC50 value of 6.0 nM. LEO 39652 is used for topical research of Atopic dermatitis (AD) .
    LEO 39652
  • HY-169758
    CEE321

    		JAK Inflammation/Immunology
    CEE321 is a potent pan-JAK inhibitor with an IC50 value of 54 nM. CEE321 potently inhibits biomarkers associated with atopic dermatitis .
    CEE321
  • HY-12348
    LEO 29102

    		Phosphodiesterase (PDE) Inflammation/Immunology
    LEO 29102 is a potent phosphodiesterase 4 (PDE4) inhibitor with an IC50 value of 5 nM. LEO 29102 inhibits TNFα release. LEO 29102 has the potential for the research of atopic dermatitis .
    LEO 29102
  • HY-B1365R
    Prednicarbate (Standard)

    		Reference Standards Glucocorticoid Receptor Inflammation/Immunology
    Prednicarbate (Standard) is the analytical standard of Prednicarbate. This product is intended for research and analytical applications. Prednicarbate is a topical corticosteroid agent. Prednicarbate can be used for the research of inflammatory skin diseases, such as atopic dermatitis .
    Prednicarbate (Standard)
  • HY-P991258
    CNTO-5825

    		Interleukin Related Inflammation/Immunology
    CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis .
    CNTO-5825
  • HY-168033
    AhR agonist 8

    		Aryl Hydrocarbon Receptor Inflammation/Immunology
    AhR agonist 8 (compound 9) is a potent Aryl Hydrocarbon Receptor (AhR) agonist with an EC50 of 0.154 nM. AhR agonist 8 can be used in the study of psoriasis and atopic dermatitis .
    AhR agonist 8
  • HY-132847
    Vibozilimod

    SCD-044

    		 LPL Receptor Inflammation/Immunology
    Vibozilimod (SCD-044, Example 33) is an orally active and selective S1PR1/EDG1 agonist with an EC50 of less than 1 nM. Vibozilimod has immunomodulatory activity and can reduce the number of lymphocytes. Vibozilimod can be used in the research of inflammatory diseases such as psoriasis and atopic dermatitis .
    Vibozilimod
  • HY-174905
    Quecitinib

    QY201

    		 JAK Cytochrome P450 Inflammation/Immunology
    Quecitinib (QY201) is an orally active JAK1/TYK2 dual inhibitor. Quecitinib is also a substrate of cytochrome P450 3A and is mainly metabolized to mono-oxide and glucuronidation products. Quecitinib has favorable pharmacokinetic properties as well as safety. Quecitinib can be used in the research of atopic dermatitis and other autoimmune diseases .
    Quecitinib
  • HY-176527
    (Rac)-TUL01101

    		JAK Inflammation/Immunology
    (Rac)-TUL01101 (Compound I) is a selective JAK kinase inhibitor. (Rac)-TUL01101 can be used in the research of various diseases such as rheumatoid arthritis, atopic dermatitis, and alopecia areata .
    (Rac)-TUL01101
  • HY-144683
    PF-07038124

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PF-07038124 is a PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2. PF-07038124 shows inhibitory activities against IL-13, IL4, and IFNγ (IC50=125, 4.1, 1.06 nM, respectively). PF-07038124 can be used for research of atopic dermatitis and plaque psoriasis .
    PF-07038124
  • HY-144683A
    PF-07038124 hydrochloride

    		Phosphodiesterase (PDE) Inflammation/Immunology
    PF-07038124 hydrochloride is a PDE4 inhibitor with an IC50 of 0.5 nM for PDE4B2. PF-07038124 hydrochloride shows inhibitory activities against IL-13, IL4, and IFNγ (IC50=125, 4.1, 1.06 nM, respectively). PF-07038124 hydrochloride can be used for research of atopic dermatitis and plaque psoriasis .
    PF-07038124 hydrochloride
  • HY-172806
    PARP14 inhibitor 1

    		PARP Inflammation/Immunology
    PARP14 inhibitor 1 (compound Q22) is a selective PARP14 inhibitor with an IC50 of 5.52 nM. PARP14 inhibitor 1 also exhibits anti-inflammatory effects and a half life of 182 min in mouse liver microsomes. PARP14 inhibitor 1 can be utilized in atopic dermatitis research .
    PARP14 inhibitor 1
  • HY-17010
    Retapamulin
    4 Publications Verification

    SB-275833

    		 Bacterial Antibiotic Infection Cancer
    Retapamulin (SB-275833) is a topical antibiotic that binds Staphylococcus aureus and E. coli ribosomes with a Kd of 3 nM. Retapamulin can be used in researches of atopic dermatitis and prostate cancer .
    Retapamulin
  • HY-P10796
    YARA peptide

    		MAPKAPK2 (MK2) Inflammation/Immunology
    YARA peptide, a cell-penetrating peptide, is a MK2 inhibitor. YARA-loaded nanoparticles decreases the levels of inflammatory cytokines (IL-1β, IL-6, and TNF-α) in an ex vivo skin culture model. YARA peptide is promising for research of atopic dermatitis (AD) .
    YARA peptide
  • HY-B1616
    Clobetasone butyrate
    1 Publications Verification

    		 Glucocorticoid Receptor Inflammation/Immunology
    Clobetasone butyrate is a synthetic glucocorticoid and has topical anti-inflammatory activity especially in skin. Clobetasone butyrate can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis .
    Clobetasone butyrate
  • HY-148074
    Zelnecirnon

    RPT193

    		 CCR Inflammation/Immunology
    Zelnecirnon (RPT193) is an orally active inhibitor of CCR4, blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. Zelnecirnon can be used for allergic inflammation in atopic dermatitis, asthma, and other diseases research .
    Zelnecirnon
  • HY-P99162
    Nemolizumab

    CIM331; CD14152

    		 Interleukin Related Inflammation/Immunology
    Nemolizumab (CIM331) is a humanized monoclonal antibody that targets the human interleukin-31 receptor a, preventing interleukin-31 (IL-31) from binding to its receptor and the subsequent signaling. Nemolizumab can help reduce itching and sleep disturbances, and it is being studied for atopic dermatitis (AD) .
    Nemolizumab
  • HY-P99053
    Tralokinumab
    2 Publications Verification

    CAT354

    		 Interleukin Related Apoptosis Caspase Cadherin Inflammation/Immunology
    Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis .
    Tralokinumab
  • HY-P99955
    Rocatinlimab

    AMG 451; KHK4083

    		 Orexin Receptor (OX Receptor) Infection Inflammation/Immunology
    Rocatinlimab (AMG 451) (KHK4083) is a fully human immunoglobulin G1 (IgG1) anti-OX40 monoclonal antibody. Rocatinlimab can be used for the research of atopic dermatitis (AD) .
    Rocatinlimab
  • HY-109085
    Difamilast
    3 Publications Verification

    OPA-15406

    		 Phosphodiesterase (PDE) Inflammation/Immunology
    Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD) .
    Difamilast
  • HY-P99555
    Tomaralimab

    OPN-305

    		 Toll-like Receptor (TLR) MyD88 NOD-like Receptor (NLR) Tau Protein Interleukin Related Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Tomaralimab (OPN-305) is a humanized anti-TLR2 IgG4 monoclonal antibody. Tomaralimab inhibits TLR2, MyD88, NLRP3, and reduces pro-inflammatory cytokine (IL-1β, IL-6, IL-8) production. Tomaralimab reduces tau pathology. Tomaralimab improves cognition, atopic dermatitis. Tomaralimab has anticancer effects on pancreatic ductal adenocarcinoma. Tomaralimab is being studied in myelodysplastic syndrome (MDS), atopic dermatitis, pancreatic ductal adenocarcinoma, Alzheimer's disease, and myocardial ischemia/reperfusion injury .
    Tomaralimab
  • HY-P991614
    IBI356

    		TNF Receptor Inflammation/Immunology
    IBI356 is a humanized monoclonal antibody inhibitor targeting OX40L/CD134L/CD252. IBI356 can be used to study chronic inflammatory skin diseases, such as atopic dermatitis .
    IBI356
  • HY-173601
    JAK3-IN-17

    		JAK Inflammation/Immunology
    JAK3-IN-17 (Compound X15) is an orally active JAK3 inhibitor (IC50: 14.56 nM). JAK3-IN-17 inhibits the production of IL-2 and IL-6 in a DNCB-induced mouse atopic dermatitis model and exhibits anti-inflammatory activity .
    JAK3-IN-17
  • HY-P991252
    XmAb-7195

    AIMab-7195

    		 Histamine Receptor Inflammation/Immunology
    XmAb-7195 (AIMab-7195) is a human monoclonal antibody (mAb) targeting IGHE. XmAb-7195 can be used in Food hypersensitivity, Allergic asthma, Allergic rhinitis, Atopic dermatitis and Conjunctivitis research .
    XmAb-7195
  • HY-P99519
    Vixarelimab
    1 Publications Verification

    KPL-716

    		 Interleukin Related Inflammation/Immunology
    Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) receptor β subunit monoclonal antibody. Vixarelimab inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .
    Vixarelimab
  • HY-109085R
    Difamilast (Standard)

    OPA-15406 (Standard)

    		 Reference Standards Phosphodiesterase (PDE) Inflammation/Immunology
    Difamilast (Standard) is the analytical standard of Difamilast. This product is intended for research and analytical applications. Difamilast (OPA-15406) is a topical, selective and nonsteroidal phosphodiesterase-4 (PDE4) inhibitor with particularly efficient inhibition of subtype B (IC50=11.2 nM). Difamilast can be used for the research of mild to moderate atopic dermatitis (AD) .
    Difamilast (Standard)
  • HY-17010R
    Retapamulin (Standard)

    SB-275833 (Standard)

    		 Reference Standards Bacterial Antibiotic Infection Cancer
    Retapamulin (Standard) is the analytical standard of Retapamulin. This product is intended for research and analytical applications. Retapamulin (SB-275833) is a topical antibiotic that binds Staphylococcus aureus and E. coli ribosomes with a Kd of 3 nM. Retapamulin can be used in researches of atopic dermatitis and prostate cancer[1][2][8].
    Retapamulin (Standard)
  • HY-B1616R
    Clobetasone butyrate (Standard)

    		Reference Standards Glucocorticoid Receptor Inflammation/Immunology
    Clobetasone butyrate (Standard) is the analytical standard of Clobetasone butyrate. This product is intended for research and analytical applications. Clobetasone butyrate is a synthetic glucocorticoid and has topical anti-inflammatory activity especially in skin. Clobetasone butyrate can be used to relieve corticosteroid-responsive dermatoses, including atopic dermatitis and psoriasis .
    Clobetasone butyrate (Standard)
  • HY-13723A
    Pimecrolimus hydrate

    SDZ-ASM 981 hydrate

    		 Phosphatase Inflammation/Immunology
    Pimecrolimus hydrate (SDZ-ASM 981 hydrate) is a potent, nonsteroid and orally active calcineurin inhibitor. Pimecrolimus hydrate shows anti-inflammatory activity. Pimecrolimus hydrate has the potential for the research of atopic dermatitis and oral erosive lichen planus .
    Pimecrolimus hydrate
  • HY-P991162
    Tilrekimig

    		Interleukin Related Inflammation/Immunology
    Tilrekimig is a monoclonal antibody targeting human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). Tilrekimig is promising for research of allergic and inflammatory diseases, such as asthma and atopic dermatitis .
    Tilrekimig
  • HY-P991720
    Tepilukimig

    		Interleukin Related Inflammation/Immunology
    Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research .
    Tepilukimig
  • HY-170977
    JAK1/STAT3-IN-1

    		JAK STAT Inflammation/Immunology
    JAK1/STAT3-IN-1 (compound 4f) is an anti-AD (atopic dermatitis) agent by inhibiting JAK1/STAT3 signaling pathway. JAK1/STAT3-IN-1 inhibits NO generation with an IC50 of 2.17 μM. JAK1/STAT3-IN-1 improves the skin condition of AD-like mice, reduces inflammatory infiltration, inhibits the expressions of p-JAK1/JAK1 and p-STAT3/STAT3, and mitigates the excessive immune response on Calcipotriol (HY-10001) (MC903)-induced AD-like mice .
    JAK1/STAT3-IN-1
  • HY-169864
    KRO-105714

    		LPL Receptor Inflammation/Immunology
    KRO-105714 is the antagonist for sphingosine phosphocholine receptor (SPC Receptor) and sphingosine-1-phosphate receptor 1 (S1P1 Receptor) (IC50=79.2 nM). KRO-105714 inhibits SPC-induced proliferation of NIH3T3 (IC50=5.6 nM), inhibits SPC-induced cell migration (IC50=0.59 μM) and tube formation in HUVECs. KRO-105714 inhibits SPC-induced generation of IL-4 and IL-5, exhibits anti-inflammtory efficacy in mouse atopic dermatitis models .
    KRO-105714
  • HY-P991598
    MOR-106

    MOR12743; MOR03207

    		 Interleukin Related NF-κB Inflammation/Immunology
    MOR-106 (MOR12743) is a humanized anti-IL-17C IgG1 monoclonal antibody. MOR-106 inhibits the NF-κB signaling pathway by specifically binding to IL-17C (IC50 = 59 pM for human IL-17C, IC50 = 55 pM for mouse IL-17C). MOR-106 can effectively inhibit skin inflammation and reduce related inflammatory factors in animal models of psoriasis and atopic dermatitis .
    MOR-106
  • HY-100009
    Ufenamate

    Flufenamic acid butyl ester; Butyl flufenamate

    		 COX Prostaglandin Receptor Inflammation/Immunology
    Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug that can be used in the study of skin diseases such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliary rashes and atopic dermatitis. Ufenamate has a certain photoprotective effect, reduces the degree of skin erythema and swelling in the photoaging model, downregulates the expression level of COX-2 and can promote the healing of mouse skull defects by secreting BMP2 .
    Ufenamate
  • HY-P5898
    Z-Val-Val-Nle-diazomethylketone

    Z-Val-Val-Nle-CHN2

    		 Cathepsin MHC Inflammation/Immunology
    Z-Val-Val-Nle-diazomethylketone is a cathepsin S (CATS) inhibitor. Z-Val-Val-Nle-diazomethylketone significantly inhibits the IFNg-induced upregulation of the MHCII molecules HLA-DR and Ii-p33/35 with an increase of Ii-p10 protein level. Z-Val-Val-Nle-diazomethylketone can be used for dermatological diseases like psoriasis, atopic dermatitis and actinic keratosis research .
    Z-Val-Val-Nle-diazomethylketone
  • HY-175764
    FIP22

    		PROTACs IRAK NF-κB p38 MAPK TNF Receptor Interleukin Related Inflammation/Immunology
    FIP22 is a potent and selective IRAK4 PROTAC degrader (HEK293T cells: DC50 = 3.2 nM; THP-1 cells: DC50 = 10.6 nM). FIP22 induces the ubiquitin-proteasome system by forming an IRAK4-FIP22-CRBN ternary complex (EC50 = 12.63 nM), thereby potently blocking IRAK4-mediated NF-κB and MAPK signaling pathways. FIP22 can be used for the study of atopic dermatitis (Pink: IRAK4 ligand (HY-175765); Blue: CRBN ligand (HY-W087383); Black: Linker (HY-46871)) .
    FIP22
  • HY-111167
    AN-2898

    		Phosphodiesterase (PDE) Interleukin Related TNF Receptor IFNAR Inflammation/Immunology
    AN-2898 is a selective PDE4 inhibitor with IC50 of 0.027 μM over other phosphodiesterase enzymes, such as PDE1A, PDE2A and PDE3A. AN-2898 also potently inhibits PDE4 subtypes (PDE4B1, PDE4A1A and PDE4D2). AN-2898 significantly inhibits the production of TNF-α, IL-2, IFN-γ, IL-5 and IL-10. AN-2898 can be used for mild to moderate atopic dermatitis (AD) and psoriasis research .
    AN-2898
  • HY-P990281
    Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3)

    		Interleukin Related Inflammation/Immunology
    Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) is a rat-derived IgG1 λ type antibody inhibitor, targeting to mouse CD25/IL-2Rα. Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) can deplete CD25+ T cells. Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) can be used for the researches of immunology and inflammation, such as atopic dermatitis .
    Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3)
  • HY-163498
    NLRP3-IN-37

    		NOD-like Receptor (NLR) Neurological Disease Inflammation/Immunology
    NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC50: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury .
    NLRP3-IN-37
  • HY-P99025
    Lebrikizumab
    1 Publications Verification

    TNX-650; MILR1444A; RG3637

    		 Interleukin Related Neurological Disease Inflammation/Immunology
    Lebrikizumab (TNX-650) is an IgG4 humanized anti-interleukin-13 (IL-13) mAb with anti-itch effects that specifically binds to IL-13 in a non-receptor binding domain and inhibits its function. Lebrikizumab inhibits the IL-13 driven Th2 inflammatory response and blocks the signaling of IL-4Rα/IL-13Rα1. Lebrikizumab can be used for the research of asthma, atopic dermatitis and neuroinflammatory diseases .
    Lebrikizumab
  • HY-14939
    Vapitadine

    		Histamine Receptor Inflammation/Immunology
    Vapitadine is a non-sedative antihistamine compound that alleviates itching associated with atopic dermatitis.
    Vapitadine
  • HY-145351
    BAY 1003803

    		Glucocorticoid Receptor Inflammation/Immunology
    BAY 1003803 is a glucocorticoid receptor agonist for the topical research of psoriasis or severe atopic dermatitis.
    BAY 1003803
  • HY-148013
    K284-6111

    		Glycosidase Amyloid-β NF-κB COX ERK NO Synthase Interleukin Related Neurological Disease Inflammation/Immunology
    K284-6111 is a high-affinity and orally active CHI3L1 inhibitor, and inhibits CHI3L1 expression. K284-6111 inhibits ERK and NF-κB pathway. K284-6111 suppresses nuclear translocation of p50 and p65, and phosphorylation of IκB. K284-6111 improves memory dysfunction by alleviating amyloidogenesis and neuroinflammation, with the reduction of inflammatory proteins (eg: iNOS, COX-2, GFAP, and Iba-1). K284-6111 reduces atopic-like skin inflammation and inhibits LPS (HY-D1056) -induced liver injury. K284-6111 can be used for the study of Alzheimer's diseases and sepsis like hepatic injury .
    K284-6111
  • HY-18706
    trans-Tranilast

    trans-MK-341; trans-SB 252218

    		 Angiotensin Receptor Cardiovascular Disease Inflammation/Immunology Endocrinology
    trans-Tranilast (trans-MK-341) is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.
    trans-Tranilast
  • HY-106714
    Clocortolone pivalate

    		Drug Metabolite Inflammation/Immunology
    Clocortolone pivalate is a synthetic glucocorticoid corticosteroid and corticosteroid ester. Clocortolone pivalate is indicated for seborrheic dermatitis, contact dermatitis, atopic dermatitis and psoriasis .
    Clocortolone pivalate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: